A Phase II Trial of Oxaliplatin and Pemetrexed in Hormone Refractory Prostate Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 14 Mar 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 10 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 29 Apr 2011 Additional trial identifiers (NCT01338792, NCI2011-00500) identified, actual patient number is 47 according to ClinicalTrials.go